Keytruda, a cancer drug developed by Merck & Co., has become a financial burden for many patients in India due to its high cost and fixed dosing model. Approved by the U.S. Food and Drug Administration (FDA) in 2014, Keytruda is now widely used for various cancers, generating approximately $29.5 billion in revenue for 2024. However, oncologists argue that the standardized 200mg dose, regardless of patient weight, leads to over-medication and increased costs. Experts suggest that a shift towards weight-based dosing could make the drug more accessible and effective. Studies indicate that a lower dose of 50mg every six weeks can yield similar results to the standard dose, yet Merck's patient assistance programs only cover the higher dosage. Additionally, the drug is only available in 100mg vials, complicating the administration of smaller doses. This situation has led to calls for changes in treatment protocols to ensure that patients can afford and access necessary cancer therapies.